Loading clinical trials...
Loading clinical trials...
Identification of Metabolite Biomarkers Related to Acute Rejection of Patients With Kidney Transplantation
The development of acute rejection can only be considered in cases with increasing serum creatinine in patients with kidney transplantation. However, the serum creatinine itself is not specific but also accurate for detection of acute rejection. So The specific biomarker is required for acute rejection of kidney transplant. In this study, the investigators will enroll 200 consecutive kidney transplant patients in Seoul National University Hospital and follow up. Serial collection of urine and serum will be done. Acute rejection specific urine metabolite will be found by LC MS/MS.
Age
18 - 70 years
Sex
ALL
Healthy Volunteers
No
Seoul National University Hospital
Seoul, South Korea
Start Date
June 28, 2016
Primary Completion Date
July 30, 2023
Completion Date
July 31, 2023
Last Updated
May 20, 2022
200
ESTIMATED participants
Lead Sponsor
Seoul National University Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07294547